SubsidieMeestersContraBand: the only heart failure medical device that is placed outside the heart
ContraBand is an implantable device designed to restore heart function in CHF patients, aiming for a 2024 launch and generating significant revenue while creating over 95 jobs in Europe.
Projectdetails
Introduction
Worldwide, 26 million people suffer from Congestive Heart Failure (CHF), a chronic condition that worsens with time and leads to staggering healthcare costs and a significant reduction in quality of life.
Project Overview
ContraBand is an implantable device aiming to restore heart function in patients suffering from left ventricle failure.
Benefits of ContraBand
ContraBand's benefits include:
- Built-in fail-safe for full reversibility of functionality
- Tremendous ease of use due to its proprietary stent-within-a-stent design and transcatheter delivery system
- Full clinical flexibility to be compatible with pharmacotherapies and other CHF devices
Development and Launch
In the project, we will finalize clinical development and introduce ContraBand into clinical routines in Europe.
Financial Expectations
We expect to launch ContraBand in 2024, generating:
- 15M in revenues in 2025
- 60M in revenues in 2026
Job Creation
Before market launch, we will create over 95 jobs at the company in strategic locations in Europe.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.999 |
| Totale projectbegroting | € 3.850.718 |
Tijdlijn
| Startdatum | 1-12-2022 |
| Einddatum | 30-11-2024 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- RESTORE MEDICAL LTDpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A revolutionary technology platform for providing life-saving treatment for end-stage heart failure patientsreBEAT is an innovative heart support technology that safely assists both sides of the heart, aiming to improve treatment accessibility and cost-effectiveness for end-stage heart failure patients. | EIC Accelerator | € 2.499.999 | 2023 | Details |
Transcatheter Ventricular Repair Device for treatment of Heart Failure PatientsCardiac Success aims to develop the V-sling, a transcatheter device to enhance heart function in heart failure patients, through product optimization and pre-clinical testing. | EIC Accelerator | € 2.500.000 | 2022 | Details |
The first heart failure therapy management point-of-care device with multiplex and multimodal sensorCardioCap is a handheld POC device that uses a finger-prick blood sample to simultaneously assess heart failure severity through four biomarkers, aiming to reduce re-hospitalization and mortality rates by 30%. | EIC Accelerator | € 2.499.999 | 2025 | Details |
Innovative, minimally invasive device to support the natural movement of the heart in heart failure patientsSyntach CS is an innovative implantable device that restores natural heart movement in patients with left ventricular heart failure, enhancing cardiac function through synchronized support. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Saving patients from severe heart failureThe ICOMS FlowMaker® is a novel intracardiac assist device designed to improve the quality of life for severe heart failure patients, aiming for EU market entry by 2026 through clinical trials. | EIC Accelerator | € 2.500.000 | 2022 | Details |
A revolutionary technology platform for providing life-saving treatment for end-stage heart failure patients
reBEAT is an innovative heart support technology that safely assists both sides of the heart, aiming to improve treatment accessibility and cost-effectiveness for end-stage heart failure patients.
Transcatheter Ventricular Repair Device for treatment of Heart Failure Patients
Cardiac Success aims to develop the V-sling, a transcatheter device to enhance heart function in heart failure patients, through product optimization and pre-clinical testing.
The first heart failure therapy management point-of-care device with multiplex and multimodal sensor
CardioCap is a handheld POC device that uses a finger-prick blood sample to simultaneously assess heart failure severity through four biomarkers, aiming to reduce re-hospitalization and mortality rates by 30%.
Innovative, minimally invasive device to support the natural movement of the heart in heart failure patients
Syntach CS is an innovative implantable device that restores natural heart movement in patients with left ventricular heart failure, enhancing cardiac function through synchronized support.
Saving patients from severe heart failure
The ICOMS FlowMaker® is a novel intracardiac assist device designed to improve the quality of life for severe heart failure patients, aiming for EU market entry by 2026 through clinical trials.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Implantable sensors and ultrasonic data link with triggered bioresorption for next-gen wireless cardiac monitoringThe 2ND-CHANCE project aims to develop bioresorbable implants for continuous cardiac monitoring post-surgery, reducing rehospitalization risks and eliminating the need for removal surgery. | ERC Starting... | € 2.500.000 | 2022 | Details |
Mechanical design concept for Cardiac Recovery Assist DeviceCardiacBooster ontwikkelt een veilig mechanisch device voor hartondersteuning bij acuut hartfalen, met focus op haalbaarheid en validatie via testen en samenwerking met derden. | Mkb-innovati... | € 20.000 | 2020 | Details |
CLOBT: Cardiale Levensreddende Ondersteuning Booster TechnoCardiacBooster heeft een innovatief apparaat ontwikkeld dat het hart van binnenuit ondersteunt, met betere resultaten en minder risico's dan bestaande mechanische ondersteuningssystemen voor cardiogene shockpatiënten. | Mkb-innovati... | € 155.376 | 2020 | Details |
HeartGuard: Thuismonitoring van patiënt met hartfalen halveert aantal ziekenhuisopnamenDit project ontwikkelt een thuismonitoringsysteem voor hartfalenpatiënten dat met AI-gestuurde data-analyse ziekenhuisopnames met 44% kan verminderen en de zorg efficiënt verbetert. | Mkb-innovati... | € 332.500 | 2023 | Details |
Novel microsensing platform for remote patient monitoringThe FORESEE project aims to advance implantable microstimulators for remote monitoring of chronic heart failure, enhancing patient care and market access for 10.5 million potential users. | EIC Transition | € 2.499.051 | 2023 | Details |
Implantable sensors and ultrasonic data link with triggered bioresorption for next-gen wireless cardiac monitoring
The 2ND-CHANCE project aims to develop bioresorbable implants for continuous cardiac monitoring post-surgery, reducing rehospitalization risks and eliminating the need for removal surgery.
Mechanical design concept for Cardiac Recovery Assist Device
CardiacBooster ontwikkelt een veilig mechanisch device voor hartondersteuning bij acuut hartfalen, met focus op haalbaarheid en validatie via testen en samenwerking met derden.
CLOBT: Cardiale Levensreddende Ondersteuning Booster Techno
CardiacBooster heeft een innovatief apparaat ontwikkeld dat het hart van binnenuit ondersteunt, met betere resultaten en minder risico's dan bestaande mechanische ondersteuningssystemen voor cardiogene shockpatiënten.
HeartGuard: Thuismonitoring van patiënt met hartfalen halveert aantal ziekenhuisopnamen
Dit project ontwikkelt een thuismonitoringsysteem voor hartfalenpatiënten dat met AI-gestuurde data-analyse ziekenhuisopnames met 44% kan verminderen en de zorg efficiënt verbetert.
Novel microsensing platform for remote patient monitoring
The FORESEE project aims to advance implantable microstimulators for remote monitoring of chronic heart failure, enhancing patient care and market access for 10.5 million potential users.